ZYN's FDA Authorization: What It Means for 20 Nicotine Pouch Products 

On January 16, 2025, the FDA authorized the marketing of 20 ZYN nicotine pouch products through the Pre-Market Tobacco Product Application (PMTA) pathway. The decision marked the FDA’s first authorization of products commonly described as nicotine pouches. 

According to the FDA, their review considered the products’ potential benefits and risks to the population as a whole, including adults who use tobacco and the risk of youth initiation. The authorization allows these specific ZYN products to be legally marketed in the United States, but it does not mean they are approved as smoking cessation products. 

Update: As of June 30, 2026, the FDA has taken this one step further, authorize these 20 ZYNs as Modified Risk Tobacco Products (MRTPs). These orders allow the products to be marketed with the following claim: “Using ZYN instead of cigarettes puts you at lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis." 

The FDA’s marketing and modified-risk orders apply to 10 ZYN varieties, each available in 3mg and 6mg nicotine strengths (20 products in total). 

The FDA determined that marketing these 20 products was appropriate for the protection of public health. The agency’s evaluation considered their potential benefits to adults who use tobacco alongside potential risks, including youth use. 

It’s worth noting that ZYN’s 3 new flavors and ZYN Ultra range are covered by a separate pending application.   

Nicotine pouches are used orally and do not involve burning or combustion. As a result, they do not produce smoke or ash and can be used without spitting.  

For adults aged 21 and older who already use nicotine, the FDA’s decisions provide clearer regulatory information about 20 specific ZYN products and how their risks compare with cigarettes. They also demonstrate the distinction between a product being authorized for sale and being allowed to carry a specific modified-risk claim. 

The data show that these nicotine pouch products meet the bar by benefiting adults who smoke cigarettes or use smokeless tobacco and completely switch to these products.

Matthew Farrelly 

Ph.D., FDA's Center for Tobacco Products

The FDA further stated that ZYN’s manufacturer “has provided evidence from a study showing that a substantial proportion of adults who use cigarettes and/or smokeless tobacco products completely switched to the newly authorized nicotine pouch products.”

While ZYN has received FDA marketing authorization, it is important to note that it is not FDA-approved for smoking cessation.  

The FDA’s review and authorization of specific ZYN products have brought greater regulatory clarity to nicotine pouches and strengthened their place in discussions about alternatives to cigarettes. 

As the nicotine industry continues to grow, the priority will be balancing innovation with public health—giving adult consumers access to authorized alternatives while maintaining responsible marketing practices. 

At Nicokick, we see these decisions as an important step in the continued evolution of smoke-free nicotine products and more informed consumer choice.